What Axcelis Technologies, Inc. told the SEC could break it.

China has represented a significant portion of Axcelis' sales, and U.S. export controls directly constrain which Chinese customers it can sell to. Its major Chinese customer SMIC is on the U.S. Entity List (shippable only to certain mature-process fabs under a 2020 licensing policy), and other Chinese chipmakers are on the Entity List without such a policy. With 83.7% of revenue international, tightening or reinterpretation of these controls is a structural, policy-driven headwind to a material revenue base. Bridged to the China node.

“U.S. export controls impact our ability to sell to certain customers in China, a country that has represented a significant portion of our sales in recent years.”

Axcelis flags fast-moving trade policy: in Aug 2025 the Federal Circuit ruled the administration's tariffs exceeded presidential authority (affirmed by the Supreme Court in Feb 2026), after which an executive order imposed a new 10% 'global tariff' with stated intent to raise it to 15%. Because Axcelis ships ~84% of revenue internationally, largely as exports from U.S. manufacturing facilities, new global tariffs and retaliatory measures could raise costs and dampen demand. Specific and dated, though not yet quantified for the company — bridged to the 2025 tariff policy node.

Axcelis sells big-ticket ion-implant systems to a small set of chipmakers, so revenue is lumpy and concentrated: one (unnamed) customer was 11.0% of consolidated revenue in 2025, and its top ten customers were 55.2% of net sales (up from 45.9% in 2024). No customer is under a long-term purchase agreement, so order timing/cancellations from any large account swing results. The broader market is concentrated too — the top-20 chipmakers are ~86% of semi-cap-equipment spending. Largest customer unnamed → register risk (the named SMIC relationship is captured as a graph edge).

“For the year ended December 31, 2025, one customer accounted for 11.0% of consolidated revenues.”

Some components and sub-assemblies in Axcelis' products are obtained from a sole source or a limited group of suppliers; while the core ion-source/implant technology is in-house, non-core items (vacuum systems, wafer handling, commodity-level components) are outsourced to global partners. A disruption at a sole-source supplier — from economic conditions or otherwise — could impair its ability to deliver systems to customers. Suppliers unnamed → register risk.

“Some of the components and sub-assemblies included in our products are obtained either from a sole source or a limited group of suppliers.”